CheckMate 040 | Simulations | CheckMate 040 | Simulations | |
Nivolumab | Combination: arm A | |||
No of patients | 214 | 1365 | 50 | 1365 |
Complete response, no (%) | 3 (1) | 23 (1.7) | 4 (8) | 16 (1.2) |
Partial response, no (%) | 39 (18) | 242 (17.7) | 12 (24) | 299 (21.9) |
Stable disease, no (%) | 96 (45) | 618 (45.3) | 9 (18) | 673 (49.3) |
Progressive disease, no (%) | 68 (32) | 482 (35.3) | 20 (40) | 377 (27.6) |
ORR % (95% CI) | 20 (15 to 26) | 19.4 (14.0 to 25.7) | 30.6 (21.8 to 48.9) | 23.1 (12 to 36) |
ORR, objective response rate.